Puma Biotechnology Inc. (PBYI)
Puma Biotechnology Statistics
Share Statistics
Puma Biotechnology has 49.61M shares outstanding. The number of shares has increased by 2.84% in one year.
| Shares Outstanding | 49.61M |
| Shares Change (YoY) | 2.84% |
| Shares Change (QoQ) | 1.07% |
| Owned by Institutions (%) | 56.56% |
| Shares Floating | 38.86M |
| Failed to Deliver (FTD) Shares | 587 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 2.88M, so 5.87% of the outstanding shares have been sold short.
| Short Interest | 2.88M |
| Short % of Shares Out | 5.87% |
| Short % of Float | 6.92% |
| Short Ratio (days to cover) | 8.04 |
Valuation Ratios
The PE ratio is 4.9 and the forward PE ratio is 8.95. Puma Biotechnology's PEG ratio is 0.14.
| PE Ratio | 4.9 |
| Forward PE | 8.95 |
| PS Ratio | 0.64 |
| Forward PS | 0.7 |
| PB Ratio | 1.61 |
| P/FCF Ratio | 3.82 |
| PEG Ratio | 0.14 |
Enterprise Valuation
Puma Biotechnology has an Enterprise Value (EV) of 131.52M.
| EV / Sales | 0.57 |
| EV / EBITDA | 2.74 |
| EV / EBIT | 3.38 |
| EV / FCF | 3.38 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.54 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 1.09 |
| Debt / FCF | 1.35 |
| Interest Coverage | 2.49 |
Financial Efficiency
Return on Equity is 32.87% and Return on Invested Capital is 23.14%.
| Return on Equity | 32.87% |
| Return on Assets | 14.19% |
| Return on Invested Capital | 23.14% |
| Revenue Per Employee | $1.34M |
| Profits Per Employee | $176.03K |
| Employee Count | 172 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 7.38 |
Taxes
| Income Tax | -6.18M |
| Effective Tax Rate | -25.63% |
Stock Price Statistics
The stock price has increased by -42.48% in the last 52 weeks. The beta is 1.33, so Puma Biotechnology's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -42.48% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 42.27 |
| Average Volume (20 Days) | 388.79K |
Income Statement
In the last 12 months, Puma Biotechnology had revenue of 230.47M and earned 30.28M in profits. Earnings per share was 0.62.
| Revenue | 230.47M |
| Gross Profit | 166.06M |
| Operating Income | 30.97M |
| Net Income | 30.28M |
| EBITDA | 48.08M |
| EBIT | 36.55M |
| Earnings Per Share (EPS) | 0.62 |
Balance Sheet
The company has 69.22M in cash and 52.36M in debt, giving a net cash position of 16.86M.
| Cash & Cash Equivalents | 69.22M |
| Total Debt | 52.36M |
| Net Cash | 16.86M |
| Retained Earnings | -1.31B |
| Total Assets | 213.33M |
| Working Capital | 51.55M |
Cash Flow
In the last 12 months, operating cash flow was 38.92M and capital expenditures -56K, giving a free cash flow of 38.86M.
| Operating Cash Flow | 38.92M |
| Capital Expenditures | -56K |
| Free Cash Flow | 38.86M |
| FCF Per Share | 0.8 |
Margins
Gross margin is 72.06%, with operating and profit margins of 13.44% and 13.14%.
| Gross Margin | 72.06% |
| Operating Margin | 13.44% |
| Pretax Margin | 10.46% |
| Profit Margin | 13.14% |
| EBITDA Margin | 20.86% |
| EBIT Margin | 13.44% |
| FCF Margin | 16.86% |
Dividends & Yields
PBYI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 20.41% |
| FCF Yield | 26.19% |
Analyst Forecast
The average price target for PBYI is $7, which is 143.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 143.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -5.97 |
| Piotroski F-Score | 6 |